Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 11;58(10):1430.
doi: 10.3390/medicina58101430.

Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia

Affiliations

Perioperative Management and Clinical Outcomes of Liver Transplantation for Children with Homozygous Familial Hypercholesterolemia

Huan-Rong Qiu et al. Medicina (Kaunas). .

Abstract

Background and Objectives: Liver transplantation (LT) has been accepted as a life-saving option as a last resort for children with homozygous familial hypercholesterolemia (HoFH). Perioperative management of LT for HoFH poses extra challenges for clinicians largely due to premature atherosclerotic cardiovascular diseases (ASCVDs). We aimed to analyze our data of pediatric LT recipients with HoFH, with special attention paid to perioperative management and clinical outcomes. Materials and Methods: After obtaining approval from the local ethics committee, the clinical data of pediatric patients with HoFH who underwent LT at our institution between January 2014 and February 2021 were retrospectively studied. Results: Six pediatric LT recipients with HoFH were included in the analysis. Although ASCVDs were common before LT, all children with HoFH survived the perioperative period without in-hospital mortality. However, one patient experienced acute myocardial infarction two months following LT and was successfully treated with medical interventions. Post-LT metabolic improvement was shown by declines in serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) levels in the early post-LT period (for TC: 14.7 ± 3.2 mmol/L vs. 5.5 ± 1.8 mmol/L, p < 0.001; for LDL-C: 10.6 ± 2.2 mmol/L vs. 3.6 ± 1.2 mmol/L, p < 0.001, respectively) and at the last follow-up (for TC: 14.7 ± 3.2 mmol/L vs. 4.5 ± 0.9 mmol/L, p = 0.001; for LDL-C: 10.6 ± 2.2 mmol/L vs. 2.8 ± 0.6 mmol/L, p = 0.001, respectively). Dietary restrictions could be lifted after LT. However, three patients required restarting lipid-lowering therapy after LT due to suboptimal LDL-C levels and progression of ASCVDs. Conclusions: Our data suggest that LT can be a safe and feasible therapeutic option for well-selected patients with HoFH, offering relaxed dietary restrictions and remarkable reductions in LDL-C levels. However, concerns remain regarding progression of ASCVDs after LT.

Keywords: cardiovascular comorbidities; children; homozygous familial hypercholesterolemia; liver transplantation; perioperative management; postoperative complications; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Changes in serum TC and LDL-C levels over time. Baseline levels were obtained in the immediate preoperative period. Post-LT levels were defined as those measured at normalization, first discharge, or one month following LT, whichever occurred first. The latest levels were obtained at the time of the last follow-up. Significant decreases in postoperative serum TC and LDL-C levels were noted. Post-LT TC levels: mean 5.5 mmol/L versus baseline levels: mean 14.7 mmol/L; p < 0.001. Latest TC levels: mean 4.5 mmol/L versus baseline levels: mean 14.7 mmol/L; p = 0.001. Post-LT LDL-C levels: mean 3.6 mmol/L versus baseline levels: mean 10.6 mmol/L; p < 0.001. Latest LDL-C levels: mean 2.8 mmol/L versus baseline levels: mean 10.6 mmol/L; p = 0.001. LDL-C low-density lipoprotein cholesterol, LT liver transplantation, TC total cholesterol.

Similar articles

Cited by

References

    1. Tromp T.R., Hartgers M.L., Hovingh G.K., Vallejo-Vaz A.J., Ray K.K., Soran H., Freiberger T., Bertolini S., Harada-Shiba M., Blom D.J., et al. Worldwide experience of homozygous familial hypercholesterolaemia: Retrospective cohort study. Lancet. 2022;399:719–728. doi: 10.1016/S0140-6736(21)02001-8. - DOI - PMC - PubMed
    1. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., Wiklund O., Hegele R.A., Raal F.J., Defesche J.C., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: Guidance for clinicians to prevent coronary heart disease: Consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013;34:3478–3490. doi: 10.1093/eurheartj/eht273. - DOI - PMC - PubMed
    1. Harada-Shiba M., Ohta T., Ohtake A., Ogura M., Dobashi K., Nohara A., Yamashita S., Yokote K., Joint Working Group by Japan Pediatric Society and Japan Atherosclerosis Society for Making Guidance of Pediatric Familial Hypercholesterolemia Guidance for Pediatric Familial Hypercholesterolemia 2017. J. Atheroscler. Thromb. 2018;25:539–553. doi: 10.5551/jat.CR002. - DOI - PMC - PubMed
    1. Cuchel M., Bruckert E., Ginsberg H.N., Raal F.J., Santos R.D., Hegele R.A., Kuivenhoven J.A., Nordestgaard B.G., Descamps O.S., Steinhagen-Thiessen E., et al. Homozygous familial hypercholesterolaemia: New insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur. Heart J. 2014;35:2146–2157. doi: 10.1093/eurheartj/ehu274. - DOI - PMC - PubMed
    1. Daniels S.R., Gidding S.S., de Ferranti S.D., National Lipid Association Expert Panel on Familial Hypercholesterolemia Pediatric aspects of familial hypercholesterolemias: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 2011;5:S30–S37. doi: 10.1016/j.jacl.2011.03.453. - DOI - PubMed

Substances